How a Hospital Superbug Is Learning to Defeat Our Last-Resort Antibiotic

A common hospital bacterium is evolving mutations that neutralize the drug called in when nothing else works — but there is an unexpected twist.

Ceftazidime-avibactam (CZA) is the antibiotic of last resort for one of the most dangerous hospital-acquired pathogens: Pseudomonas aeruginosa. When carbapenems — the heavy-duty class of antibiotics that usually stops this bug — fail, CZA is the next line of defense. But new evidence suggests that defense is already cracking.

Researchers from Tongji University in China analyzed samples from two critically ill patients infected with P. aeruginosa and discovered that the bacteria had developed genetic mutations in a key enzyme called KPC. These mutations, designated KPC-71 and KPC-78, allow the bacteria to neutralize CZA by dismantling its built-in shield — the avibactam component that normally protects the antibiotic from being broken down. The findings were published in Microbiology Spectrum in July 2026.

The See-Saw Effect

Here is where the story takes an unexpected turn. The same mutations that help P. aeruginosa resist CZA also appear to weaken the bacteria's defenses against older carbapenem drugs — the very class of antibiotics that CZA was designed to replace. This "see-saw effect," as the researchers call it, means that the newly evolved strains may be treatable with imipenem or meropenem, two older antibiotics that had lost their effectiveness against earlier versions of the bug.

However, the researchers warn that relying on older drugs is not a permanent solution. The bacteria could just as easily evolve back, regaining carbapenem resistance while keeping their new CZA resistance. "Reversion mutations could theoretically restore carbapenem resistance under imipenem or meropenem pressure," the team cautions.

Why This Matters

Pseudomonas aeruginosa is found virtually everywhere in the environment — in soil, water, and hospitals. It is particularly dangerous because it thrives on medical equipment: ventilators, catheters, and surgical instruments. For patients already weakened by illness or surgery, a P. aeruginosa infection can be life-threatening. The specific strain involved in this study, known as ST463, has already raised concerns among health officials in China for its high infectivity and strong drug resistance even without the new mutations.

The findings underscore the urgency of antibiotic stewardship. "The shrinking effectiveness of available antimicrobial therapies has intensified the global threat," the researchers write. They call for increased clinical monitoring of CZA resistance development during treatment, especially in regions where the ST463 lineage is spreading.

What Comes Next

The see-saw effect offers a narrow but real therapeutic window. If clinicians can identify these specific KPC mutations early, they may be able to switch patients to older carbapenem drugs before the bacteria have a chance to adapt further. The challenge is that current diagnostic tests do not routinely sequence the KPC enzyme — they only check whether the bacteria grow or die in the presence of the drug. Adding molecular surveillance to standard hospital protocols could buy valuable time in the arms race against antibiotic resistance.

— A knowledge brief from X5H, based on findings published in Microbiology Spectrum, July 2026.